About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Extended Use of Common Antibiotics may Cut Down Hospitalization Rates Among COPD Patients

by Kathy Jones on May 24, 2013 at 7:46 PM
Font : A-A+

 Extended Use of Common Antibiotics may Cut Down Hospitalization Rates Among COPD Patients

A comparison of hospitalization rates among chronic obstructive pulmonary disease (COPD) patients treated with a 12-month course of azithromycin and those treated with placebo reveals that extended used of the antibiotic may prolong the time between hospitalizations for patients.

The results of the current analysis will be presented at the ATS 2013 International Conference.

Advertisement

"Preventing respiratory-related re-hospitalizations is a key component of COPD therapy, and previous research has shown that a 12-month course of azithromycin decreases the risk of acute exacerbations of COPD," said lead author Fernando Martinez, MD, MS, director of pulmonary diagnostic services at the University of Michigan Health System. "COPD patients who have been hospitalized for a respiratory event are at particularly high risk for re-hospitalization, and we wanted to examine whether chronic azithromycin therapy might provide a benefit in these patients."

For their study, the researchers used clinical data gathered from a previous study of azithromycin use conducted by the COPD Clinical Research Network (CCRN), a group of research centers established to study new treatments for COPD and funded by the National Heart, Lung, and Blood Institute (NHLBI). All patients who participated in the study either had experienced an acute exacerbation of COPD in the 12 months prior to study enrollment or had used supplemental oxygen at the time of enrollment. Patients were randomized to receive either a daily dose of 250 mg of azithromycin or placebo for one year. In response to a recent FDA report suggesting a link between azithromycin and cardiovascular events, Dr. Martinez emphasized that the study excluded individuals with a heart condition known as prolonged QTc and those at risk for the condition.
Advertisement

The researchers noted the time any patient had an initial respiratory-related hospitalization and then measured the time that elapsed before the same patient was re-hospitalized, keeping track of the total number of hospitalizations as well as those that were due to respiratory-related causes such as pneumonia, influenza, bronchitis, asthma or acute exacerbation of COPD.

Next, the researchers compared that elapsed time in patients treated with azithromycin with those receiving placebo, adjusting their comparison for differences in age, gender and health and lifestyle indicators, and found that patients treated with azithromycin had a longer period between their first respiratory related hospitalization and the next hospitalization compared to patients treated with placebo. Among those re-hospitalized, the study found that age, gender, inhaled medication regimens and respiration measurements were similar between patients treated with azithromycin and those who received placebo.

"When comparing patients treated with azithromycin and those who received placebo, we found that there was a significant delay from the first respiratory-related hospitalization to the next one among those treated with azithromycin," said Dr. Martinez, who is also a professor of internal medicine at the university. "Also, looking at re-hospitalization due to any cause, we found there was a trend toward a delay between first and subsequent all-cause hospitalizations for patients taking azithromycin compared to those that did not take it."

While these results suggest prolonged azithromycin therapy may offer significant benefits to COPD patients, Dr. Martinez cautions that right now, the results of the post-hoc analysis provide an interesting hypothesis but no clear answers with regard to therapeutic recommendations. Additional studies will be needed to confirm the results, he added.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cholamandalam Health Insurance Policies MRSA - The Super Bug Pneumoconiosis Pulmonary Arterial Hypertension Chronic Obstructive Pulmonary Disease Antibiotics Eye Infections Natural Antibiotics to Fight Bacterial Infections Emphysema Vancomycin-Resistant Enterococci (VRE) 

Recommended Reading
Chronic Obstructive Pulmonary Disease
COPD includes respiratory tract disorders that cause obstruction to airflow. These are chronic .....
Pulmonary Embolism
Pulmonary embolism (PE) is a complication that results from a block in the main artery supplying ......
Pulmonary Arterial Hypertension
It can be a serious condition affecting the heart. It is defined as mean pulmonary arterial ......
Pulmonary Embolism and Deep Vein Thrombosis
Deep vein thrombosis (DVT) is a condition where blood clots develop usually in the deep veins of ......
Antibiotics
Antibiotics are among the most used and abused medications. This article explains some general featu...
Cholamandalam Health Insurance Policies
Cholamandalam MS General Insurance Company (Chola MS) a joint venture of Murugappa Group & Mitsui Su...
Emphysema
Emphysema is a chronic obstructive pulmonary disease, marked by alveolar damage, and reduced air flo...
Eye Infections
Eye infection is a common problem that often causes pain and discomfort to the eyes. Common symptoms...
MRSA - The Super Bug
MRSA infection is the most dreaded hospital or community acquired infection that can become ......
Natural Antibiotics to Fight Bacterial Infections
Fighting infections the natural way and preventing them is always more effective than consuming medi...
Pneumoconiosis
Pneumoconiosis is a group of lung diseases caused by inhaled dust particles. It causes inflammation ...
Vancomycin-Resistant Enterococci (VRE)
Enterococci are a group of gram-negative bacteria that mostly inhabit the human gut. At present ther...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use